Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Danish expanded newborn screening is a successful preventive public health programme

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Analgesics use and withdrawal in people with dementia - a register-based Danish study and a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Regional and socioeconomic variation in survival of melanoma patients in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Treatment of osteoarthritis with autologous and microfragmented adipose tissue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Children with dyskinetic cerebral palsy are severely affected as compared to bilateral spastic cerebral palsy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fatal kakeksi ved mitokondriel neurogastrointestinal encefalomyopati.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Tuberous sclerosis complex (TSC) is a rare autosomal dominant multi-organ disease. In TSC, epilepsy is frequent and often treatment refractory. Dysfunction of the tumour-suppressing hamartin/tuberin complex leads to an over-activated mammalian target of rapamycin (mTOR) signalling pathway and uncontrolled cell growth. Protocolled treatment of TSC-associated epilepsy with the mTOR inhibitor everolimus has recently been approved by The Danish Medicines Council in Denmark.

METHODS: Clinical data on the first Danish paediatric patients treated with everolimus for epilepsy and a review of the literature are presented.

RESULTS: Four patients met the inclusion criteria and had been treated for more than 12 months. Onset of epilepsy was at a median age of 1.1 years (range: 0.3-3.3 years) and current age was 3.4 years (range: 2.2-7.4 years). The previous median number of antiepileptic drugs was 5.0 (range: 2-10) and the concomitant median number of antiepileptic drugs was 2.5 (range: 1-4). Several other treatment modalities had been or were still being applied, including ketogenic diet (n = 3), vagus nerve stimulation (n = 1) and epilepsy surgery (n = 2). The number of focal seizures was in the 20-160 range per week before everolimus. All patients had a > 50% seizure reduction after 12 months of everolimus treatment. One patient became seizure free. Side effects were mild and self-limiting.

CONCLUSIONS: Early data on everolimus as an adjunctive treatment in TSC-associated epilepsy are promising with regards to both effect and tolerability.

FUNDING: none.

TRIAL REGISTRATION: not relevant.

OriginalsprogEngelsk
TidsskriftDanish Medical Journal
Vol/bind66
Udgave nummer12
Antal sider6
ISSN1603-9629
StatusUdgivet - dec. 2019

Bibliografisk note

Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

ID: 58572662